TP53 and cutaneous melanoma: We have previously reported the anti-cancer activity of MDM2i in combination with GSK2830371 in cutaneous melanoma and showed that GSK2830371 potentiates the effect of MDM2i on melanoma cells by increasing the function and stability of p53 in a p53-dependent manner [21].